IO Biotech (NASDAQ:IOBT) Adopts Amended and Restated Bylaws

On December 13, 2024, IO Biotech, Inc. (the “Company”), disclosed changes in a recent 8-K filing with the Securities and Exchange Commission regarding the adoption of amended and restated bylaws. The Board of Directors of the Company approved the amended and restated bylaws, effective immediately. These modified bylaws, known as the “Amended and Restated Bylaws,” introduce several key amendments and updates.

The alterations within the Amended and Restated Bylaws include revisions to procedural mechanics and disclosure requirements concerning stockholder nominations of directors, submission of proposals for business at stockholder meetings, and general director eligibility. Additionally, they address matters related to Rule 14a-19 under the Exchange Act, update procedures and rules for stockholder meetings, ensure compliance with recent changes to the Delaware General Corporation Law, and enact other minor administrative changes.

The summary of amendments brought forth by the Amended and Restated Bylaws is supplemented by the full text of the document attached as Exhibit 3.1 to the Current Report on Form 8-K filed by IO Biotech. Interested parties are encouraged to refer to the complete text for detailed information.

Furthermore, in compliance with regulatory requirements, IO Biotech provided a list of exhibits associated with the filing. Exhibit 3.1 details the Amended and Restated Bylaws of IO Biotech, Inc., set to be effective from December 13, 2024, while Exhibit 104 comprises the Cover Page Interactive Data File, embedded within the Inline XBRL document.

Lastly, Mai-Britt Zocca, Ph.D., the Chief Executive Officer of IO Biotech, signed the report on behalf of the Company as per the obligations of the Securities Exchange Act of 1934. This filing signifies the Company’s commitment to transparent governance practices and adherence to regulatory standards.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read IO Biotech’s 8K filing here.

About IO Biotech

IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.